NCT00320658View on ClinicalTrials.gov

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Malaria
Interventions
BIOLOGICAL

MSP1 42-C1/Alhydrogel

Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)

BIOLOGICAL

CPG 7909

Adjuvant

Trial Locations (1)

20037

Center for Immunization Research, Johns Hopkins University, Bloomberg School of Public Health, Washington D.C.

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00320658 - Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant | Biotech Hunter | Biotech Hunter